API manufacturer in China handed warning letter after failing to respond to the regulator’s requests for information
An active pharmaceutical ingredient manufacturer in China reportedly lied to the FDA about whether it will continue shipping products into the US and did not …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.